Collectively, these results suggest that alterations of ATRX preferentially target its enzymatic functions rather than its protein-protein interactions, thus explaining why mutations in ATRX partner genes (i.e., DAXX, EZH2, SP100) are not frequent and not an alternative to ATRX alteration in sarcomas. The gene discussed is ATRX; the disease is sarcoma.